Previous Close | 1.3800 |
Open | 1.4200 |
Bid | 1.3700 x 1200 |
Ask | 1.4200 x 1300 |
Day's Range | 1.3550 - 1.4200 |
52 Week Range | 1.1000 - 5.1000 |
Volume | |
Avg. Volume | 758,100 |
Market Cap | 24.599M |
Beta (5Y Monthly) | 1.33 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.7460 |
Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.10 |
Subscribe to Yahoo Finance Plus to view Fair Value for BCDA
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -26.67% and 68.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
SUNNYVALE, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2022 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2022 with the Securities and Exchange Commission. The Company will also hold an update conference call today at 4:30 PM ET. Following management’s formal rem
This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any of Tom’s potential 100x picks, subscribe to his mailing list here. A Recession Is Now “Inevitable” On Thursday, the Commerce Department reported that U.S. GDP had shrunk 1.4% from the prior year. “There are two realistic scenarios for how the coming months play out. Both end with recession,” noted Lisa Beilfuss of the Barron’s Advisor editorial team. “Either the Fed sufficiently fights inflat